Research funding and citations in papers of Nobel Laureates in Physics, Chemistry and Medicine, 2019-2020

Purpose:The goal of this study is a comparative analysis of the relation between funding(a main driver for scientific research)and citations in papers of Nobel Laureates in physics,chemistry and medicine over 2019-2020 and the same relation in these research fields as a whole.Design/methodology/approach:This study utilizes a power law model to explore the relationship between research funding and citations of related papers.The study here analyzes 3,539 recorded documents by Nobel Laureates in physics,chemistry and medicine and a broader dataset of 183,016 documents related to the fields of physics,medicine,and chemistry recorded in the Web of Science database.Findings:Results reveal that in chemistry and medicine,funded researches published in papers of Nobel Laureates have higher citations than unfunded studies published in articles;vice versa high citations of Nobel Laureates in physics are for unfunded studies published in papers.Instead,when overall data of publications and citations in physics,chemistry and medicine are analyzed,all papers based on funded researches show higher citations than unfunded ones.Originality/value:Results clarify the driving role of research funding for science diffusion that are systematized in general properties:a)articles concerning funded researches receive more citations than(un)funded studies published in papers of physics,chemistry and medicine sciences,generating a high Matthew effect(a higher growth of citations with the increase in the number of papers);b)research funding increases the citations of articles in fields oriented to applied research(e.g.,chemistry and medicine)more than fields oriented towards basic research(e.g.,physics).Practical implications:The results here explain some characteristics of scientific development and diffusion,highlighting the critical role of research funding in fostering citations and the expansion of scientific knowledge.This finding can support decision-making of policymakers and R&D managers to improve the effectiveness in allocating financial resources in science policies to generate a higher positive scientific and societal impact.

General laws of funding for scientific citations:how citations change in funded and unfunded research between basic and applied sciences

Purpose:The goal of this study is to analyze the relationship between funded and unfunded papers and their citations in both basic and applied sciences.Design/methodology/approach:A power law model analyzes the relationship between research funding and citations of papers using 831,337 documents recorded in the Web of Science database.Findings:The original results reveal general characteristics of the diffusion of science in research fields:a)Funded articles receive higher citations compared to unfunded papers in journals;b)Funded articles exhibit a super-linear growth in citations,surpassing the increase seen in unfunded articles.This finding reveals a higher diffusion of scientific knowledge in funded articles.Moreover,c)funded articles in both basic and applied sciences demonstrate a similar expected change in citations,equivalent to about 1.23%,when the number of funded papers increases by 1%in journals.This result suggests,for the first time,that funding effect of scientific research is an invariant driver,irrespective of the nature of the basic or applied sciences.Originality/value:This evidence suggests empirical laws of funding for scientific citations that explain the importance of robust funding mechanisms for achieving impactful research outcomes in science and society.These findings here also highlight that funding for scientific research is a critical driving force in supporting citations and the dissemination of scientific knowledge in recorded documents in both basic and applied sciences.Practical implications:This comprehensive result provides a holistic view of the relationship between funding and citation performance in science to guide policymakers and R&D managers with science policies by directing funding to research in promoting the scientific development and higher diffusion of results for the progress of human society.

Unequal Distribution of Innovation Efforts for Neglected Tropical Diseases: The Role of Funding Evaluation Criteria

Background: International research and innovation efforts for neglected tropical diseases have increased in recent decades due to disparities in overall health research funding in relation to global burden of disease. However, within the field of neglected tropical diseases some seem far more neglected than others. In this research the aim is to investigate the distribution of resources and efforts, as well as the mechanisms that underpin funding allocation for neglected tropical diseases. Methodology: A systematic literature review was conducted to establish a comprehensive overview of known indicators for innovation efforts related to a wide range of neglected tropical diseases. Articles were selected based on a subjective evaluation of their relevance, the presence of original data, and the breadth of their scope. This was followed by thirteen in-depth open-ended interviews with representatives of private, public and philanthropic funding organizations, concerning evaluation criteria for funding research proposals. Results: The findings reveal a large difference in the extent to which the individual diseases are neglected with notable differences between absolute and relative efforts. Criteria used in the evaluation of research proposals relate to potential impact, the probability of success and strategic fit. Private organizations prioritize strategic fit and economic impact;philanthropic organizations prioritize short-term societal impact;and public generally prioritize the probability of success by accounting for follow-up funding and involvement of industry. Funding decisions of different types of organizations are highly interrelated. Conclusions: This study shows that the evaluation of funding proposals introduces and retains unequal funding distribution, reinforcing the relative neglect of diseases. Societal impact is the primary rationale for funding but application of it as a funding criterion is associated with significant challenges. Furthermore, current application of evaluation criteria leads to a primary focus on short-term impact. Through current practice, the relatively most neglected diseases will remain so, and a long-term strategy is needed to resolve this.

Research on the Influence of Government R&D Funding and Enterprise R&D Investment on the Innovation Efficiency of Pharmaceutical Industry

Objective To study the effect of government R&D funding and enterprise R&D input on innovation efficiency of China’s pharmaceutical industry.Methods Based on the inter-provincial panel data of China’s pharmaceutical industry from 2009 to 2019,the stochastic frontier analysis method was used to study the influence of government R&D funding and enterprise R&D input on the innovation efficiency.Results and Conclusion With 1%increase in government R&D funding,the innovation efficiency of enterprises will increase by 0.122%.When R&D investment increases by 1%,innovation efficiency will increase by 0.169%.Both government R&D funding and enterprise R&D investment promote the innovation efficiency of pharmaceutical enterprises,but the increase of enterprise R&D investment contributes more to the improvement of pharmaceutical innovation efficiency.

Patients Involved in Funding Research.A Look Back at the Unique Experience of the ECLAIR Working Group of Canceropole CLARA

This article aims to share an innovative experience of organizing and funding research involving those most directly affected:patients.The“ECLAIR”working group of the Canceropole Lyon Auvergne-Rhone-Alpes(CLARA)was created at the end of 2020 with the goal of contributing to the development of a call for projects on the patient experience in oncology,which was launched in January 2021.Initially composed of 8 members,including 7 patients,coordinated by a project manager from CLARA,the ECLAIR working group actively participated in drafting the specifications of the call for projects,developing the eligibility criteria for applications,revising the evaluation and selection criteria for projects,and monitoring the selected projects.This experience was repeated twice.With significant freedom of action,the working group made two decisions that strongly demonstrate the commitment to supporting research partnerships and the active involvement of those affected:firstly,by making partnership a mandatory requirement for the eligibility of applications,and secondly,by conducting the selection of projects themselves,after an independent scientific evaluation phase.Seeking to shed light on the“black box”of partnership,the article also presents the concrete modalities of interaction among the working group members,the adjustments made between different editions of the call for projects,and the relationships maintained with CLARA.

The relation between funding by the National Institutes of Health and the burden of disease

Background:The Institute of Medicine has proposed that the amount of disease-specific research funding provided by the National Institutes of Health(NIH)be systematically and consistently compared with the burden of disease for society.Methods:We performed a cross-sectional study comparing estimates of disease-specific funding in 1996 with data on six measures of the burden of disease.

The relation between funding by the National Institutes of Health and the burden of disease

Background:The Institute of Medicine has proposed that the amount of disease-specific research funding provided by the National Institutes of Health(NIH)be systematically and consistently compared with the burden of disease for society.Methods:We performed a cross-sectional study comparing estimates of disease-specific funding in 1996 with data on six measures of the burden of disease.The measures were total mortality,years of life lost,and number of hospital days in 1994 and incidence,prevalence,and disability-adjusted life-years(one disability-adjusted life-year is defined as the loss of one year of healthy life to disease)in 1990.With the use of these measures as explanatory variables in a regression analysis,predicted funding was calculated and compared with actual funding.

石家庄市R&D经费投入现状分析与对策研究

R&D经费投入强度,是国际上通用的衡量一个国家或者地区科技投入强度的重要指标,成为评价其科技实力、核心竞争力和创新程度的重要标准。本文在对石家庄市研发投入开展调研的基础上,对R&D经费投入开展总体分析、结构分析、横纵向比较分析,找出存在的问题,提出加大政府对科研活动的支持、大力发展新兴产业、重视研发投入统计等对策与建议。

DRG付费下重点稽核违规行为智能审核和监控规则库比较研究

目的通过对重点稽核违规行为智能审核和监控规则库进行规则类别、重点稽核行为、规则与行为对应程度比较分析,为完善我国DRG付费下医保重点稽核违规行为智能审核和监控提供参考。方法检索收集2019年5月20日—2023年12月31日各地医保局发布的DRG付费管理办法等政策文件及数据库中DRG付费智能审核监控规则的相关文献,针对其中与DRG付费下重点稽核违规行为相关的规则,采用文献分析法和比较分析法进行归纳和分析。结果DRG付费下重点稽核违规行为智能审核规则可分为逻辑判断类和参数指标类两大类,审核规则与重点稽核行为的对应程度各异。结论(1)统一全国重点稽核规则,保证规则的普适性、全面性;(2)深挖区域违规行为现状,强化地方特色;(3)逻辑判断类规则“提质”与参数指标类规则“增量”共进;(4)强化新型违规行为的科学研究,建立更具针对性的监管规则。

临床试验对医保基金支出的影响研究——基于某肿瘤医院化疗组DRG的实证分析

目的 探讨临床试验对医保支付的客观影响,为DRG支付方式改革的持续推进提供参考。方法 搜集某肿瘤医院2022年3月15日—2023年3月14日出院的RE1化疗组资料,对超支付限额病例的现状进行描述,并对其影响因素进行logistic回归分析。结果 DRG病例10 971例,其中临床试验组病例占5.42%。临床试验组和非临床实验组超DRG支付限额占比分别为7.56%和25.26%,差异均有统计学意义(P<0.001)。logistic回归分析结果显示,患者进入临床试验,其超支付标准的风险程度降低89.2%,是否靶向治疗、是否静脉置管、住院日、是否免疫治疗、是否多学科会诊、性别依次是病例超支的风险因素。结论 临床试验有助于医院维持医保基金的结余平衡。医院要做好主动管理,为支付制度的完善打好基础。区分联合治疗将是化疗组DRG分组细化的方向。

政府R&D补贴的技术创新效应分析--基于2009-2021年中国的经验数据

政府R&D补贴既可以通过提供公共服务的方式直接作用于技术创新,也可以通过对社会资本的引导作用间接影响技术创新,其总效应取决于两种影响的方向与大小。基于2009—2021年中国的经验数据,建立了由技术创新方程和引致方程共同组成的动态模型,对政府R&D补贴的技术创新效应进行了实证分析。结果发现:持续增加的政府R&D补贴带来了国内专利授权数量的稳定增加,技术创新效应较为显著;政府R&D补贴不仅对技术创新产生了积极的直接影响,也通过引导社会资本投资于研发领域而对技术创新产生了积极的间接影响;政府R&D补贴的技术创新效应存在区域差异,中东部地区为正,而西部地区为负。提高资金使用效率、积极引导社会资本投资技术研发、努力改善欠发达地区的研发环境,无疑是提高政府R&D补贴技术创新效应的必要选择。

云南省R&D经费投入结构动态研究

为研究云南省“十二五”以来R&D经费投入结构变化,分析R&D经费投入现状,并与全国,东、中、西部地区及临近省份进行了对比;从资金来源和资金配置视角,运用Cobb-Douglas效用函数及其修正模型对R&D经费投入结构展开动态分析。结果表明:云南省R&D经费投入结构不尽合理,资金来源中政府资金占比较低且呈下降趋势,资金配置中基础研究和应用研究投入不足,与最优结构偏离程度较大。针对存在的问题,提出持续加大政府R&D经费投入力度、围绕产业链提升基础研究和应用研究比重的建议。

政府R&D资助对OFDI逆向绿色创新的影响机制研究

应用中国分省区层面数据并采用面板门槛模型,实证考察了政府R&D资助影响OFDI逆向绿色创新的动态效应。研究发现,OFDI对国内绿色创新产生了显著的驱动效应,但这种影响呈现出明显的先负后正的“U”型动态演化特征;政府R&D资助会正向调节OFDI逆向绿色创新溢出,且存在最适宜于OFDI逆向绿色创新的政府R&D资助区间(0.366,0.428],过高或过低强度的政府R&D资助均会在一定程度上造成OFDI逆向绿色创新的红利损失;政府R&D资助调节下OFDI对绿色创新的动态影响具有显著时空异质性,即在时空维度上存在“激励效应”与“挤出效应”交替演化的鲜明特征。

R&D资本化背景下我国TFP增长率再测算

研究与试验发展(R&D)资本对经济增长和科技创新作用日益凸显,但对于R&D资本的核算亟待完善。本文基于SNA2008和CSNA2016框架,将R&D支出作为资本形成,对我国各省份物质资本存量和R&D资本存量进行规范化测算,使用随机前沿分析法重新估算1991—2019年间的全要素生产率(TFP)增长率。研究发现:第一,我国R&D资本存量规模呈总体递增和地区聚集趋势;第二,1991—2019年间,我国广义TFP增长率年平均增幅为2.10%,对经济增长存在正向作用;第三,将TFP增长率分解为技术进步、前沿技术效率和规模效应,发现技术进步对TFP增长率的贡献最大,是推动我国TFP增长的主导力量,但却呈现逐年递减的趋势;第四,随着我国对R&D投入的不断增加与重视,R&D对我国广义TFP增长率的贡献呈现递增的趋势,R&D的贡献逐渐成为推动我国科技进步的主要力量。

Beyond authorship: Analyzing contributions in PLOS ONE and the challenges of appropriate attribution

Purpose:This study aims to evaluate the accuracy of authorship attributions in scientific publications,focusing on the fairness and precision of individual contributions within academic works.Design/methodology/approach:The study analyzes 81,823 publications from the journal PLOS ONE,covering the period from January 2018 to June 2023.It examines the authorship attributions within these publications to try and determine the prevalence of inappropriate authorship.It also investigates the demographic and professional profiles of affected authors,exploring trends and potential factors contributing to inaccuracies in authorship.Findings:Surprisingly,9.14%of articles feature at least one author with inappropriate authorship,affecting over 14,000 individuals(2.56%of the sample).Inappropriate authorship is more concentrated in Asia,Africa,and specific European countries like Italy.Established researchers with significant publication records and those affiliated with companies or nonprofits show higher instances of potential monetary authorship.Research limitations:Our findings are based on contributions as declared by the authors,which implies a degree of trust in their transparency.However,this reliance on self-reporting may introduce biases or inaccuracies into the dataset.Further research could employ additional verification methods to enhance the reliability of the findings.Practical implications:These findings have significant implications for journal publishers,Beyond authorship:Analyzing contributions in PLOS ONE and Maddi,A.,&the challenges of appropriate attribution highlighting the necessity for robust control mechanisms to ensure the integrity of authorship attributions.Moreover,researchers must exercise discernment in determining when to acknowledge a contributor and when to include them in the author list.Addressing these issues is crucial for maintaining the credibility and fairness of academic publications.Originality/value:This study contributes to an understanding of critical issues within academic authorship,shedding light on the prevalence and impact of inappropriate authorship attributions.By calling for a nuanced approach to ensure accurate credit is given where it is due,the study underscores the importance of upholding ethical standards in scholarly publishing.

DRG付费下医生异化行为监管的实践及思考

目的:探讨DRG付费下医生异化行为的监管策略,为医保部门加强监管提供参考。方法:分析DRG付费下医生异化行为的典型表现和原因,以样本医院为例,总结医院加强医生异化行为监管的做法和成效。结果:与2020年相比,2023年样本医院被扣减病例数减少215例,扣款金额减少338.57万元,15日内再入院病例从567例减少到208例。结论:DRG付费下,医院应构建全方位监管体系,关联资源消耗,加强智能审核,确定DRG监管靶点,进行精准管控,完善绩效考核方案,减少医生异化行为,促进医院高质量发展。

企业R&D支出费用化资本化与会计盈余管理行为选择研究——基于中国部分上市公司的经验数据

本文基于中国部分上市公司的数据,选取R&D支出全部费用化、全部资本化、部分资本化3个虚拟变量及R&D支出费用化金额、资本化金额用以表征R&D支出披露形式,研究上市公司R&D支出会计政策选择是否与盈余管理程度相关,进而检验R&D支出会计处理盈余管理路径,即检验R&D支出费用化、资本化的确定依据是否受其他非准则因素影响。研究结果显示,有条件资本化会计处理可能成为管理层盈余管理手段,包括应计盈余管理和真实盈余管理。在确定R&D支出费用化金额、资本化金额及R&D支出费用化强度上,管理层除了依据会计准则,还要依据当期利润情况、所得税负、利润质量、审计成本、利润平滑和公司独立性的影响。

粤港澳大湾区企业R&D活动特征研究

基于上市公司数据,对粤港澳大湾区企业R&D活动的行业、规模、经济类型以及研发效益的时滞特征进行研究。发现的典型事实有:(1)企业R&D活动具有明显的行业特征,高强度的研发企业主要聚集于信息通信技术(ICT)、医药制造、仪器仪表和设备制造等高新技术行业;(2)企业研发活动与企业规模有关,大型企业的研发规模大,但是小型企业研发强度最高,大型企业最低;(3)经济类型不同企业的研发投入强度没有显著差异,长期以来认为“国有企业研发强度和效率不如民营企业”的断言不符合实际;(4)企业研发强度与自身经营状况联系密切,盈利能力越强的企业R&D投入强度通常越高,盈利不佳的企业通常难以进行高强度的研发;(5)企业R&D研发效益的产生往往具有相当长的时滞,ICT行业中软件服务业研发效益的产生通常需要两年的滞后期,硬件设备制造业通常在五年以上。为促使企业持续加大R&D投入,尽快实现将粤港澳大湾区建成全球科技创新高地和新兴产业重要策源地的目标,一方面要大力培育企业经营者的企业家精神,另一方面应进一步改革税制,降低制造业增值税税率,增强企业的盈利能力和持续加大研发投入强度的能力。

Interpretation of the Standards of Basic Dataset of Chronic Diseases Behavior Risk Factor Surveillance in Adults

BACKGROUND China’s Behavioral Risk Factor Surveillance System(BRFSS)originated from the World Bankfunded HealthⅦLoan Project in the 1990s,which conducted behavioral risk factor surveillance in seven cities and one province^([1]).Drawing on the World Health Organization’s(WHO)STEPwise approach to surveillance(STEPs)and the U.S.Behavioral Risk Factor Surveillance System(BRFSS)^([2,3]).

2021年副省级城市R&D经费投入分析

2017—2021年,副省级城市的R&D经费投入都保持持续增长的态势。深圳的R&D经费投入在副省级城市中一直处于遥遥领先的地位,西安由于科研院所和高校众多,2017年R&D经费投入总量在副省级城市中排名第四,2021年排名第七,被资源禀赋相似的南京、成都、武汉等城市超越。西安由于GDP总量不高,R&D经费投入强度一直保持在5%左右,2020年被深圳反超。基于数据的可获得性,本文从2021年副省级城市的R&D经费投入总量、R&D经费投入强度等方面进行解读和分析,并结合分析结果提出相关建议,以供参考。